Compare Amphastar Pharmaceuticals Inc (AMPH) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Uranium Energy Corp trades at $10.41 (market cap $5.21B). The key difference: Uranium Energy Corp is far larger — about 6.3× Amphastar Pharmaceuticals Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | UEC | |
|---|---|---|
Market Cap | $826.08M | $5.21B |
Sector | Health | Energy |
52-Week High | $30.81 | $20.14 |
52-Week Low | $16.87 | $6.59 |
Enterprise Value | $1.22B | $4.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
UEC trades at $10.53, up 3.64% today, but technical indicators show a bearish trend with strong selling pressure. The company reported widening losses with negative net income margins and zero revenue in recent quarters, though it maintains $794 million in liquid assets and no debt. Analyst consensus remains overwhelmingly bullish with 87.5% buy ratings, citing strategic positioning in uranium production.
Investment outlook hinges on execution of production ramp-ups and uranium price recovery. Key opportunities include strategic assets and strong liquidity, while risks involve persistent losses, regulatory delays, and volatile commodity prices. The stock faces near-term pressure from weak fundamentals despite long-term nuclear energy tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
